100 Most Popular
You can buy or sell CRISPR and other stocks, options, ETFs, and crypto commission-free!
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. Read More The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.
52 Week High
52 Week Low
100 Most Popular
Call For CRISPR Moratorium Echoes Early Days Of Gene Therapy
A group of influential scientists have urged that clinical use of CRISPR be put on hold in the wake of the Chinese gene-edited baby debacle.
PR NewswireMar 12
University of California granted new CRISPR-Cas9 patent, extending its patent portfolio for genome editing
BERKELEY, Calif., March 12, 2019 /PRNewswire/ -- The University of California announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 10,227,611, covering use of single molecule RNA guides and Cas9 protein in any cell, thus creating efficient and effective ways for scientists to target and edit genes. This patent is co-owned by The Regents of the University of California, the University of Vienna, and Emmanuelle Charpentier. The CRISPR-Cas9 DNA-targeting technology, inve...
Simply Wall StMar 7
Is CRISPR Therapeutics AG (NASDAQ:CRSP) As Strong As Its Balance Sheet Indicates?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as CRISPR Therapeutics AG (NASDAQ:CRSP), with a market capitalization of US$2.0b, rarely draw their attention from the investing community.
Expected May 7, Pre-Market